JPWO2023048275A1 - - Google Patents
Info
- Publication number
- JPWO2023048275A1 JPWO2023048275A1 JP2023549769A JP2023549769A JPWO2023048275A1 JP WO2023048275 A1 JPWO2023048275 A1 JP WO2023048275A1 JP 2023549769 A JP2023549769 A JP 2023549769A JP 2023549769 A JP2023549769 A JP 2023549769A JP WO2023048275 A1 JPWO2023048275 A1 JP WO2023048275A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021157187 | 2021-09-27 | ||
| PCT/JP2022/035626 WO2023048275A1 (ja) | 2021-09-27 | 2022-09-26 | Ｔ細胞の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2023048275A1 true JPWO2023048275A1 (ja) | 2023-03-30 |
Family
ID=85720842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549769A Pending JPWO2023048275A1 (ja) | 2021-09-27 | 2022-09-26 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240400993A1 (ja) |
| EP (1) | EP4410965A4 (ja) |
| JP (1) | JPWO2023048275A1 (ja) |
| KR (1) | KR20240067089A (ja) |
| CN (1) | CN118056007A (ja) |
| AR (1) | AR127141A1 (ja) |
| AU (1) | AU2022349176A1 (ja) |
| CA (1) | CA3234008A1 (ja) |
| CO (1) | CO2024004812A2 (ja) |
| MX (1) | MX2024003619A (ja) |
| TW (1) | TW202330910A (ja) |
| WO (1) | WO2023048275A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022341119A1 (en) * | 2021-09-08 | 2024-03-21 | Orchard Therapeutics (Europe) Limited | Compositions and methods for treating or preventing autoimmune diseases |
| US20250230411A1 (en) * | 2022-03-23 | 2025-07-17 | Kyoto University | Method for producing regulatory t cells |
| KR20250077533A (ko) * | 2022-09-26 | 2025-05-30 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | T 세포 제조 방법 |
| CN116640728B (zh) * | 2023-07-24 | 2023-10-20 | 呈诺再生医学科技(北京)有限公司 | RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE502004001104D1 (de) | 2004-04-10 | 2006-09-14 | Henkel Kgaa | Lockenwickler |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| EP1970446B1 (en) | 2005-12-13 | 2011-08-03 | Kyoto University | Nuclear reprogramming factor |
| US7661738B2 (en) | 2006-11-28 | 2010-02-16 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
| EP3878949B1 (en) | 2007-04-07 | 2025-06-04 | Whitehead Institute for Biomedical Research | Reprogramming of somatic cells |
| WO2008151058A2 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| JP2009237558A (ja) | 2008-03-05 | 2009-10-15 | Semiconductor Energy Lab Co Ltd | 半導体装置の駆動方法 |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| SG11201401343YA (en) | 2011-09-13 | 2014-08-28 | Igor Roninson | TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY |
| BR112014019052A8 (pt) | 2012-02-02 | 2017-07-11 | Senex Biotechnology Inc | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer |
| KR20150044952A (ko) | 2012-08-23 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드 |
| CN104755477B (zh) | 2012-10-08 | 2017-09-26 | 默克专利股份公司 | 2‑氨基吡啶化合物 |
| GB201220157D0 (en) | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| KR20150092279A (ko) | 2012-12-10 | 2015-08-12 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진 |
| WO2014106606A1 (en) | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| WO2014154723A1 (en) | 2013-03-29 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyrrole derivatives for the treatment of cancer |
| WO2014180943A1 (en) * | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| WO2014194201A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Ｃｄｋ８之醫療性抑制劑及其用途 |
| JP6494631B2 (ja) | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コルチスタチン類縁体並びにその合成及び使用 |
| EP3122739B1 (en) | 2014-03-27 | 2019-01-16 | Merck Patent GmbH | Pyridyl piperidines |
| JP6529085B2 (ja) | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| US9745325B2 (en) | 2014-04-18 | 2017-08-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| WO2016009076A1 (en) | 2014-07-17 | 2016-01-21 | Merck Patent Gmbh | Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors |
| AU2016343682A1 (en) | 2015-10-30 | 2018-06-14 | The Regents Of The University Of California | Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells |
| JP7059481B2 (ja) | 2016-06-23 | 2022-04-26 | 国立大学法人京都大学 | Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法 |
| EP3494209A1 (en) * | 2016-08-05 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of mhcii restricted cd4+foxp3+ regulatory t cells and therapeutic uses thereof |
| US12006512B2 (en) | 2017-01-20 | 2024-06-11 | Kyoto University | Method for producing CD8alpha+beta+ cytotoxic t cells |
| WO2018159805A1 (ja) | 2017-03-03 | 2018-09-07 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
| KR20200019231A (ko) * | 2017-06-22 | 2020-02-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 조절 면역 세포를 제조하기 위한 방법 및 이의 용도 |
| US12060566B2 (en) * | 2017-08-22 | 2024-08-13 | The Regents Of The University Of California | Self-inactivating lentiviral vector comprising a FOXP3 expression cassette |
| AU2019256783A1 (en) * | 2018-04-18 | 2020-10-22 | Ucl Business Ltd | Engineered regulatory T cell |
| KR102847265B1 (ko) | 2018-08-10 | 2025-08-19 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Cd3 양성 세포의 제조 방법 |
| EP3842522B1 (en) * | 2018-08-22 | 2025-10-15 | The University of Osaka | Method for producing regulatory t cells |
| AU2020378228A1 (en) | 2019-11-08 | 2022-05-26 | Sangamo Therapeutics, Inc. | Generation of engineered regulatory T cells |
| US20250195655A1 (en) * | 2022-02-04 | 2025-06-19 | Kyoto University | T cell production method |
| US20250230411A1 (en) * | 2022-03-23 | 2025-07-17 | Kyoto University | Method for producing regulatory t cells |
-
2022
- 2022-09-26 MX MX2024003619A patent/MX2024003619A/es unknown
- 2022-09-26 AU AU2022349176A patent/AU2022349176A1/en active Pending
- 2022-09-26 WO PCT/JP2022/035626 patent/WO2023048275A1/ja not_active Ceased
- 2022-09-26 EP EP22873026.3A patent/EP4410965A4/en active Pending
- 2022-09-26 AR ARP220102574A patent/AR127141A1/es unknown
- 2022-09-26 TW TW111136382A patent/TW202330910A/zh unknown
- 2022-09-26 CA CA3234008A patent/CA3234008A1/en active Pending
- 2022-09-26 KR KR1020247011957A patent/KR20240067089A/ko active Pending
- 2022-09-26 CN CN202280064732.XA patent/CN118056007A/zh active Pending
- 2022-09-26 US US18/695,720 patent/US20240400993A1/en active Pending
- 2022-09-26 JP JP2023549769A patent/JPWO2023048275A1/ja active Pending
-
2024
- 2024-04-17 CO CONC2024/0004812A patent/CO2024004812A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330910A (zh) | 2023-08-01 |
| MX2024003619A (es) | 2024-04-19 |
| US20240400993A1 (en) | 2024-12-05 |
| CO2024004812A2 (es) | 2024-05-20 |
| AR127141A1 (es) | 2023-12-20 |
| CA3234008A1 (en) | 2023-03-30 |
| WO2023048275A1 (ja) | 2023-03-30 |
| CN118056007A (zh) | 2024-05-17 |
| EP4410965A4 (en) | 2025-09-24 |
| AU2022349176A1 (en) | 2024-04-11 |
| EP4410965A1 (en) | 2024-08-07 |
| KR20240067089A (ko) | 2024-05-16 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260203 |